Clinical Trials on Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer in United Kingdom

Total 3391 results

Bayer

Not yet recruiting

A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2) (SOHO-02)

Advanced Non-small Cell Lung Cancer | HER2 Mutation

United States, Korea, Republic of, Belgium, China, Hong Kong, Japan, Taiwan, Denmark, Germany, Israel, Poland, Italy, United Kingdom, Bulgaria, Czechia, Portugal, Switzerland, Greece, Turkey, Romania, Sweden, France, Singapore, Mexico, ... and more
AstraZeneca
Parexel

Active, not recruiting

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (LATIFY)

Advanced or Metastatic Non-Small Cell Lung Cancer

United States, France, Italy, Spain, Belgium, Romania, Canada, Korea, Republic of, Brazil, Hungary, Japan, China, Taiwan, Hong Kong, United Kingdom, Germany, Poland, Australia, Netherlands, Serbia, India, Argentina, Ireland
Stanford University
The American Association of Physicists in Medicine

Terminated

Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors

Pancreatic Cancer | Lung Cancer | Liver Cancer | Hepatobiliary Cancers | Hepatobiliary Cancers Liver | Lung Cancer Non-Small Cell Cancer (NSCLC) | Lung Cancer Small Cell Lung Cancer (SCLC) | Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma) | Hepatobiliary Cancers Gallbladder | Hepatobiliary Cancers...

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Withdrawn

Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
Novartis Pharmaceuticals

Completed

Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States

Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation

United States
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
Polaris Group

Terminated

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (TRAP)

Glioma | Hepatocellular Carcinoma | Uveal Melanoma | Sarcomatoid Carcinoma | Pleural Mesothelioma Malignant Advanced | Peritoneal Mesothelioma Malignant Advanced | Non-squamous Non-small Cell Lung Carcinoma

United States, United Kingdom
Bayer

Recruiting

A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Best Dose, How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, and How it Acts on Different Tumors in Participants With Advanced Solid Tumors

Advanced Solid Tumors | Non-small Cell Lung Cancer

United States, Korea, Republic of, Israel, Japan, China, Australia
Western Regional Medical Center

Terminated

Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer | Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer

United States
Karen Kelly
Bristol-Myers Squibb; National Cancer Institute (NCI); Transgene

Completed

TG4010 and Nivolumab in Patients With Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Not yet recruiting

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Metastatic Melanoma | Locally Advanced Melanoma | Metastatic Alveolar Soft Part Sarcoma | Metastatic Non Small Cell Lung Cancer | Metastatic Hepatocellular Carcinoma | Locally Advanced Hepatocellular Carcinoma | Metastatic Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer | Locally... and other conditions

United States
Taiho Oncology, Inc.

Completed

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Advanced or Metastatic Non-small Cell Lung Cancer

United States, France, Poland, Spain, Italy, Japan
Regeneron Pharmaceuticals
BioNTech SE

Recruiting

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Advanced Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, Georgia, Taiwan, Germany, Turkey
University College, London

Completed

Cisplatin, Vinorelbine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery (SOCCAR)

Lung Cancer

United Kingdom
The Christie NHS Foundation Trust

Unknown

Gemcitabine Plus Supportive Care in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lung Cancer

United Kingdom
Washington University School of Medicine
Arcus Biosciences, Inc.

Active, not recruiting

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Adenocarcinoma | Advanced Non-Small Cell Lung Cancer | Squamous Cell Carcinoma | Advanced NSCLC | Adenosquamous Carcinoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer

Tobacco Use Disorder | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB...

United States
NanoMab Technology (UK) Limited
King's College London; Guy's and St Thomas' NHS Foundation Trust

Recruiting

PD-L1 Expression in Lung Cancer (PELICAN)

Non-Small Cell Lung Cancer

United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer (PALOMA-3)

Advanced or Metastatic Non-small Cell Lung Cancer

Italy, United States, Germany, Japan, China, Korea, Republic of, Israel, Portugal, Taiwan, Thailand, Malaysia, United Kingdom, Australia, Turkey, Poland, Spain, Brazil, Canada, Argentina, France
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | TNBC - Triple-Negative Breast Cancer | NSCLC Stage IV Without EGFR/ALK Mutation

United States, Canada
Mirati Therapeutics Inc.

Recruiting

A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Solid Tumor | Non Small Cell Lung Cancer | Advanced Solid Tumor | Colo-rectal Cancer

United States, Puerto Rico
AbbVie

Active, not recruiting

Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors

Advanced Solid Tumors Cancer | Non Small Cell Lung Cancer (NSCLC)

United States, Australia, France, Israel, Japan, Korea, Republic of, Spain, Taiwan
AstraZeneca
Daiichi Sankyo

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Korea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
Guy's and St Thomas' NHS Foundation Trust
NanoMab Technology (UK) Limited

Recruiting

PD-L1 Expression in Cancer (PECan Study). (PECan)

Melanoma | Non-small Cell Lung Cancer

United Kingdom
AstraZeneca

Completed

Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Spain, United Kingdom, France, United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bristol-Myers Squibb

Completed

Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...

United States
H. Lee Moffitt Cancer Center and Research Institute
Nestlé Health Science

Withdrawn

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢA

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI); CytoImmune Therapeutics

Active, not recruiting

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer... and other conditions

United States
GlaxoSmithKline

Completed

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Cancer

United States, Belgium, United Kingdom
M.D. Anderson Cancer Center

Terminated

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIC Lung Cancer AJCC v8 | Unresectable Lung... and other conditions

United States
Regeneron Pharmaceuticals

Active, not recruiting

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Advanced Non-small Cell Lung Cancer

United States
Roswell Park Cancer Institute

Completed

Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Washington University School of Medicine

Active, not recruiting

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IIB Non-Small Cell Lung Cancer | Stage IIIC Non-Small Cell Lung Cancer

United States
Prelude Therapeutics

Recruiting

PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation

Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancers | SMARCA4 Gene Mutation

United States, France, Spain, Singapore, Netherlands
Genzyme, a Sanofi Company

Completed

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line

United States, Czech Republic, Hungary
AstraZeneca
Daiichi Sankyo

Recruiting

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China, Korea, Republic of, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, United States, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
The Christie NHS Foundation Trust

Unknown

Paclitaxel and Carboplatin Chemotherapy Compared With Standard Chemotherapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer That Cannot Be Removed During Surgery

Lung Cancer

United Kingdom
The Christie NHS Foundation Trust

Unknown

Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin

Lung Cancer

United Kingdom
Memorial Sloan Kettering Cancer Center
AstraZeneca

Recruiting

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

NSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

United States
Emory University
Washington University Siteman Cancer Center

Active, not recruiting

An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

United States
Synta Pharmaceuticals Corp.

Terminated

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

United States, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czech Republic, Germany, Poland, Romania, Russian Federation, Serbia, Spain, United Kingdom
National Cancer Institute (NCI)

Unknown

Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Lung Cancer

United Kingdom
University Hospital Birmingham

Unknown

Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United Kingdom
Emory University
National Cancer Institute (NCI)

Recruiting

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma

United States
AstraZeneca
Quintiles, Inc.

Completed

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)

United States

Clinical Trials on Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer in United Kingdom

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations